Nootropics Index - Save on smarter supplements
Nootropics>Fatty acids, lipids & phospholipids>Conjugated Linoleic Acid
Fatty acids, lipids & phospholipids

Conjugated Linoleic Acid

Conjugated linoleic acid isomer mixture

Conjugated linoleic acid (CLA) is a mixture of linoleic-acid isomers sold mainly for body-composition goals, not cognition. Human findings suggest small changes of uncertain practical importance, not established focus, energy, or endurance effects. Compare the exact isomer mixture, oil form, labelled grams, and current product data.

Food DerivedOil BasedFat SolubleBioavailability SensitiveSports NutritionClinical ResearchMixed Evidence
Updated August 2026/4 min read/7 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What CLA is

1

Conjugated Linoleic Acid is not one molecule in a single ratio. It is a mixture of linoleic-acid isomers, especially c9,t11-CLA and t10,c12-CLA, sold as free fatty acid, triacylglycerol, powder, or softgel formats.

Evidence fit

1

CLA evidence is mostly about body composition. ODS and meta-analyses describe small average effects with uncertain practical importance. That evidence does not support focus, memory, wakefulness, mood or general nootropic claims.

Bottom line1
CLA belongs in Supplements v2 as a lipid product profile, not a nootropic recommendation. The useful shopping work is checking grams per day, isomer form, powder versus softgel parsing, and GI/metabolic safety fit.
02

Names, aliases and forms

Common NameConjugated Linoleic Acid
AbbreviationCLA
Chemical NameLinoleic acids, conjugated
Molecular FormulaC18H32O2
Lipid Formfree fatty acid or triacylglycerol CLA
03

Potential effects and evidence map

ODS summarizes CLA as a mixture of linoleic-acid isomers used in weight-management supplements, with human findings showing minimal effects on body weight and body fat. Meta-analyses report small average body-composition changes with uncertain practical importance. There is no useful evidence that CLA improves focus, memory, wakefulness or mood in healthy users.

Effect domainMagnitudeGrade
Physical energy / endurance1
CumulativeConfidence: Medium

Repeated-dose CLA body-composition evidence is mixed and small in practical effect; it does not establish physical energy or endurance benefit.

Note The C grade reflects body-composition evidence, not direct endurance evidence.

0/5
C
04

Typical dosages and timing

Research-context dose12.4-6 g/day

ODS summarizes CLA research around 2.4-6 g/day for months. This is study context, not a personal dose recommendation or an acute-effect timeline.

05

Timing & effect horizon

Effect horizonCumulative
Cumulative
Study window1Cumulative
6-12 months
06

Safety, side effects and risk profile

GI discomfort1
Confidence: High

CLA commonly raises GI tolerability issues such as abdominal discomfort, constipation, diarrhea, loose stools, nausea or dyspepsia.

Note ODS lists GI effects as the most common adverse-effect category.

2/5
B
Cardiovascular caution1
Confidence: Medium

CLA may adversely affect blood lipids or glucose homeostasis in some contexts, so metabolic and cardiovascular history should be considered.

Note Risk is context-dependent and isomer-dependent.

2/5
C
Liver / kidney caution1
Confidence: Medium

CLA has case-report links to hepatitis, with product contamination not fully ruled out, so liver history and unexplained symptoms matter.

Note Do not overstate causality, but keep the caution visible.

2/5
C
Interaction risk7
Confidence: Low

No clinical CLA medication-interaction list is established; individual review is appropriate when medicines or clinician-directed nutrition plans are already in use.

Note Metabolic and liver context does not establish a direct drug-interaction list.

1/5
D
Pregnancy / lactation caution1
Confidence: Low

Human pregnancy-outcome evidence for CLA supplements is insufficient. For breastfeeding, a possible breast-milk-fat finding needs confirmation.

Note Evidence gap and lactation uncertainty; not a CLA-specific avoid claim.

1/5
D
Evidence uncertainty2
Confidence: High

The main evidence supports at most small body-composition effects, while no cognitive benefit is established.

Note High risk of user expectation mismatch.

2/5
B
Legal / regulatory risk7
Confidence: Medium

In the United States, dietary-supplement manufacturers are responsible for safety and labeling before marketing; FDA can act against adulterated or misbranded products.

Note U.S. regulatory context only, as of 2026.

1/5
B
Tolerability1GI / metabolic markers

The most practical side effects are GI symptoms, but lipid, glucose and liver context should also be checked. CLA is not a harmless nootropic filler just because it is a fatty acid.

07

Interactions and cautions

Individual review7

No clinical CLA medication-interaction list is established. FDA advises discussing dietary supplements and medicines with a clinician or pharmacist, especially when a medicine or clinician-directed nutrition plan is already in use.

08

Legal and regulatory status

Status7

As of 2026, U.S. dietary-supplement manufacturers are responsible for safety and labeling before marketing; FDA can act against adulterated or misbranded products after marketing. This is U.S. regulatory context, not a global approval determination.

09

How it compares

Form comparison6

The dated catalog snapshot has powder and capsule entries, but variant parsing, duplicate offers, and incomplete dose or price fields make cross-form price ranking unreliable. Confirm the storefront label, isomer mixture, oil form, and labelled grams before comparing.

10

Practical buying and quality notes

  • Use only current records with a confirmed isomer mixture, oil form, labelled grams, and nonzero price. Exclude duplicate, stale, malformed, or incomplete rows from a best-price or per-dose comparison.6
11

References

  1. NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss: Health Professional Fact Sheet, CLA section.
  2. Onakpoya IJ, Posadzki PP, Watson LK, Davies LA, Ernst E. Long-term CLA supplementation and body composition: systematic review and meta-analysis. Eur J Nutr. 2012;51:127-134.
  3. Namazi N, Irandoost P, Larijani B, Azadbakht L. CLA supplementation, anthropometric indices, and body composition: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2019;59:2720-2733.
  4. PubChem Compound Summary for CID 5280644, rumenic acid.
  5. PubChem Compound Summary for CID 5282800, (10E,12Z)-octadeca-10,12-dienoic acid.
  6. NootropicsIndex CLA product catalog snapshot, 1 August 2026.
  7. U.S. Food and Drug Administration. Information for Consumers on Using Dietary Supplements.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.